Presentation Abstract

Session: Imaging Posters
Saturday, Jul 10, 2010, 11:15 AM - 1:15 PM
Presentation: IC-P-059 - Assessment of Aβ deposition in mild cognitive impairment with 18F-Florbetaben
Pres. Time: Saturday, Jul 10, 2010, 11:15 AM -12:15 PM
Location: 313-C
Category: +New imaging methods
Author(s): Kevin Ong, MD1, Victor L. Villemagne, MD1,2, Narelle Langdon, RN1, Gerhard Holl, MD3, Cornelia Reininger, MD3, Barbara Putz, PhD3, Gareth Jones1, Rachel Mulligan, PhD1, Svetlana Pejoska, RN1, Beate Rohde, PhD3, Colin L. Masters, MD2, Christopher C. Rowe, MD1.
1Austin Hospital, Melbourne, VIC, Australia, 2The Mental Health Research Institute, Melbourne, VIC, Australia, 3Bayer Schering Pharma, Berlin, Germany.
Abstract: Background:
Amyloid deposition precedes objective cognitive decline as shown in 11C-PiB PET studies. PiB use is currently limited to settings with an on-site cyclotron, so 18F’s longer half-life makes a 18F labeled amyloid tracer better suited for clinical practice where regional synthesis and distribution is possible. The purpose of the study was to determine 18F-Florbetaben retention in mild cognitive impairment (MCI) subjects compared to healthy controls (HC) and Alzheimer's disease (AD) patients.
Methods:
Twenty-six HC subjects (MMSE 29 ± 1), 43 MCI subjects (MMSE 27± 2) and 26 subjects with mild to moderate AD (MMSE 23±3) underwent 18F-Florbetaben PET studies. Aβ burden was assessed using Standardized Uptake Value normalized to cerebellar cortex (SUVR) at 90-110 minutes post injection. Cognitive scores were correlated to the PET results.
Results:
Tracer retention was significantly higher in ADs than HCs (neocortical SUVR 1.95±0.3 vs 1.28±0.2, respectively). About 50% of the MCIs presented an “AD-like” pattern of cortical retention, whilst the rest resemble a “HC-like” retention pattern. The average neocortical SUVR for the group was 1.46±0.4. Neocortical SUVR correlated with composite episodic memory score (r = -0.53, p =0.0003) and MMSE (r = - 0.4, p = 0.008) in MCI, but not in HC or AD.
Conclusions:
18F-Florbetaben PET appears valuable in assessing AD neuropathology in vivo, with similar findings as 11C-PiB PET studies. Follow-up studies on these MCI subjects will help determine the usefulness of 18F-Florbetaben PET in predicting progression to AD.
Disclosures:  K. Ong, None; V.L. Villemagne, NHMRC Grant 509166, Grants/Research Support; Bayer Schering Pharma, Consultant; N. Langdon, None; G. Holl, Bayer Schering Pharma, Employee; C. Reininger, Bayer Schering Pharma, Employee; B. Putz, Bayer Schering Pharma, Employee; G. Jones, None; R. Mulligan, NHMRC Grant 509166, Grants/Research Support; S. Pejoska, None; B. Rohde, Bayer Schering Pharma, Employee; C.L. Masters, None; C.C. Rowe, Bayer Schering Pharma, Consultant; Bayer Schering Pharma, Other financial or material support.
EMBARGO: As a reminder: All abstracts accepted for presentation at ICAD are embargoed until the date and time of presentation at the conference, unless the Alzheimer's Association provides written notice of change of date and/or time in advance. Embargo is the prohibition for copyright reasons from releasing any content from a submitted or accepted abstract to the public until after it has been presented at ICAD. Prior to presentation at ICAD, authors may not release information to the news media or the public, nor publish the results in any manner, and must ensure that colleagues and other organizations or institutions are aware of this policy. Violation of the embargo may include retraction of the accepted abstract and/or loss of privileges of presenting research at ICAD in the future.



Technical Support
Phone: 217-398-1792
Helpdesk